---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034846"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:28:22.252801+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva reports Q3 net loss of $4.0M; cash $13.2M; pre-NDA meeting with FDA on track

## Summary
- Net loss of $4.0M ($0.06 per share) for Q3 2025, compared to $8.4M ($0.25) in Q3 2024.
- Cash and cash equivalents totaled $13.2M as of September 30, 2025.
- Pre-NDA meeting with FDA planned for Q4 2025; NDA submission for schizophrenia targeted for Q2 2026.
- European patent granted covering use of brilaroxazine for treatment of pulmonary fibrosis.
- Closed public equity offering with gross proceeds of $9.0M.

## SEC filing metadata
- accession: 0001437749-25-034846
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/0001437749-25-034846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/rvph20251103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034846
- JSON: https://secwatch.observer/filing/0001437749-25-034846.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.